Ticker Details
Humacyte, Inc. Common Stock
IPO Date:	November 30, 2020
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$197.7M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.18 | 4.51%
Avg Daily Range (30 D):	$0.06 | 5.91%
Avg Daily Range (90 D):	$0.06 | 6.02%

Institutional Daily Volume
Avg Daily Volume:	2.12M
Avg Daily Volume (30 D):	13.77M
Avg Daily Volume (90 D):	9.19M

Trade Size
Avg Trade Size (Sh.):	250
Avg Trade Size (Sh.) (30 D):	565
Avg Trade Size (Sh.) (90 D):	526

Institutional Trades
Total Institutional Trades:	312
Avg Institutional Trade:	$1.49M
Avg Institutional Trade (30 D):	$2.65M
Avg Institutional Trade (90 D):	$2.05M
Avg Institutional Trade Volume:	.41M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.62M
Avg Closing Trade (30 D):	$3.66M
Avg Closing Trade (90 D):	$3.11M
Avg Closing Volume:	431.23K

News

Jun 11, 2026 @ 1:08 AM Humacyte, Inc. Announces Pricing of Public Offerin... Source: Globe Newswire

Jun 11, 2026 @ 1:08 AM Humacyte, Inc. Announces Pricing of Public Offerin... Source: Not Specified

Jun 11, 2026 @ 12:55 AM Humacyte, Inc. Announces Proposed Public Offering ... Source: Na

May 13, 2026 @ 11:00 AM Humacyte Announces First Quarter 2026 Financial Re... Source: Na

May 12, 2026 @ 12:00 PM Humacyte Appoints Dr. Todd E. Rasmussen as Chief S... Source: Humacyte, Inc.

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-.59	$-.09	$-.15
Diluted EPS	$-.59	$-.09	$-.15
Revenue	$2.02M	$.5M	$.47M
Gross Profit	$-9.58M	$-1.54M	$-8.62M
Net Income / Loss	$-97.59M	$-17.62M	$-24.8M
Operating Income / Loss	$-113.89M	$-28.94M	$-30.84M
Cost of Revenue	$11.59M	$2.04M	$9.08M
Net Cash Flow	$-64.31M	$-1.96M	$31.01M
PE Ratio